The global cancer microbiome sequencing market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors, including growing occurrences of cancer and increasing emphasis on the microbiome’s potential in the field of cancer, are fueling the growth of the market. Microbiomes are the community of microorganisms that grow or exist in an environment, such as saliva, skin layers, oral mucosa of the human body, and the gastrointestinal tract. Microbiome sequencing is a valuable tool that is used to study and analyze the microbes groups located in or out of the human body to have a better understanding of human microbes. The main aim of a microbiome research study is to understand the role and function of microbes in human health and disease. The other factors supporting the market’s growth are decreasing cost of sequencing, the rise in R&D activities, the exponential rise in the number of cancer cases worldwide, the increasing number of clinical trials, the rise in the development of novel diagnostic tools based on the microbiome for supporting physicians, increasing investments by biotechnology companies, rise in demand for microbiome sequencing services for diagnosis and early detection of the diseases, rise in world population, growing awareness of the use of microbiome sequencing technology, rise in the healthcare expenditure, rising interest of researchers in understanding the role of the microbiome in human health and disease, and immense potential for emerging submarkets.
The rising Prevalence of Cancer supports Market Growth.
Growing incidences of cancer, such as lung, cervical, breast, skin, throat, and others, are augmenting the growth of the market. According to WHO, in 2020, cancer is a major cause of death across the world, reporting approximately 10 million deaths, or about one in six deaths. The most common cancers are lung, colon and rectum, prostate cancers, and breast. There is a surge in the number of cases suffering from cancer caused due to consumption of alcohol, tobacco use, unhealthy eating choices, and sedentary lifestyle. Therefore, the need for cancer microbiome sequencing is rising, which in turn, bolsters the growth of the market. As per WHO, many cancers can be treated effectively if detected in an early stage.
Increasing Emphasis by Researchers on the Microbiome’s Potential and Rising Support from Biotechnology Companies.
The rising focus on the microbiome’s potential to diagnose and prevent various cancers is fueling the growth of the market. Various researchers are studying and researching the microbiome’s potential in the field of cancers. Researchers are being supported by biotech companies to unravel insights pertaining to the microbiome’s influence on cancer progression and manifestation. Furthermore, the development of cancer microbiome sequencing services and products has aided the research community in creating effective strategies for discovering novel cancer biomarkers allied with the microbiome, which could be used for the development of cancer microbiome sequencing products for clinical use.
Market Segmentation
The global cancer microbiome sequencing market is segmented into components, technology, application, end-user, and company. Based on components, the market is divided into kits & assays, software, and services. Based on technology, the market is divided into next-generation sequencing and polymerase chain reaction. Based on application, the market is divided into translational research and clinical diagnostics. Based on end-user, the market is divided into biotechnology & pharmaceutical companies, academic & research institutions, hospitals & clinics, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising incidences of cancer and a rise in R&D activities in the country.
Market Players
Illumina, Inc., Eurofins Scientific SE, QIAGEN NV, Thermo Fischer Scientific, Inc., Oxford Nanopore Technologies plc., OraSure Technologies, Inc., Pacific Biosciences of California, Inc., Psomagen, Inc, Prescient Medicine Holdings, Inc., and Micronoma Inc. are some of the leading companies operating in the market.
Report Scope:
In this report, global cancer microbiome sequencing market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
- Cancer Microbiome Sequencing Market, By component:
- Kits & Assays
- software
- Services
- Cancer Microbiome Sequencing Market, By technology:
- Next-Generation Sequencing
- Polymerase Chain Reaction
- Cancer Microbiome Sequencing Market, By application:
- Translational Research
- Clinical Diagnostics
- Cancer Microbiome Sequencing Market, By End User:
- Biotechnology & Pharmaceutical Companies,
- Academic & Research Institutions
- Hospitals & Clinics
- Others
- Cancer Microbiome Sequencing Market, By Region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Europe & CIS
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Turkey
- Egypt
Company Profiles: Detailed analysis of the major companies present in Global Cancer Microbiome Sequencing Market
Company Information
- Detailed analysis and profiling of additional market players (up to five).
- 1. Product Overview
- 2. Research Methodology
- 3. Executive Summary
- 4. Impact of COVID-19 on Global Cancer Microbiome Sequencing Market
- 5. Voice of Customer
- 6. Global Cancer Microbiome Sequencing Market Outlook
- 6.1. Market Size & Forecast
- 6.1.1. By Value
- 6.2. Market Share & Forecast
- 6.2.1. By Component (Kits & Assays, Software, Services)
- 6.2.2. By Technology (Next Generation Sequencing v/s Polymerase Chain Reaction)
- 6.2.3. By Application (Translational Research v/s Clinical Diagnostics)
- 6.2.4. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Hospitals & Clinics, Others)
- 6.2.5. By Company (2021)
- 6.2.6. By Region
- 6.3. Market Map
- 7. North America Cancer Microbiome Sequencing Market Outlook
- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Component
- 7.2.2. By Technology
- 7.2.3. By Application
- 7.2.4. By End User
- 7.2.5. By Country
- 7.3. North America: Country Analysis
- 7.3.1. United States Cancer Microbiome Sequencing Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.1.1. By Value
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Component
- 7.3.1.2.2. By Technology
- 7.3.1.2.3. By Application
- 7.3.1.2.4. By End User
- 7.3.2. Canada Cancer Microbiome Sequencing Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.1.1. By Value
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Component
- 7.3.2.2.2. By Technology
- 7.3.2.2.3. By Application
- 7.3.2.2.4. By End User
- 7.3.3. Mexico Cancer Microbiome Sequencing Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.1.1. By Value
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Component
- 7.3.3.2.2. By Technology
- 7.3.3.2.3. By Application
- 7.3.3.2.4. By End User
- 8. Europe Cancer Microbiome Sequencing Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Component
- 8.2.2. By Technology
- 8.2.3. By Application
- 8.2.4. By End User
- 8.2.5. By Country
- 8.3. Europe: Country Analysis
- 8.3.1. France Cancer Microbiome Sequencing Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.1.1. By Value
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Component
- 8.3.1.2.2. By Technology
- 8.3.1.2.3. By Application
- 8.3.1.2.4. By End User
- 8.3.2. Germany Cancer Microbiome Sequencing Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.1.1. By Value
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Component
- 8.3.2.2.2. By Technology
- 8.3.2.2.3. By Application
- 8.3.2.2.4. By End User
- 8.3.3. United Kingdom Cancer Microbiome Sequencing Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.1.1. By Value
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Component
- 8.3.3.2.2. By Technology
- 8.3.3.2.3. By Application
- 8.3.3.2.4. By End User
- 8.3.4. Italy Cancer Microbiome Sequencing Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.1.1. By Value
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Component
- 8.3.4.2.2. By Technology
- 8.3.4.2.3. By Application
- 8.3.4.2.4. By End User
- 8.3.5. Spain Cancer Microbiome Sequencing Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.1.1. By Value
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Component
- 8.3.5.2.2. By Technology
- 8.3.5.2.3. By Application
- 8.3.5.2.4. By End User
- 9. Asia-Pacific Cancer Microbiome Sequencing Market Outlook
- 9.1. Market Size & Forecast
- 9.1.1. By Value
- 9.2. Market Share & Forecast
- 9.2.1. By Component
- 9.2.2. By Technology
- 9.2.3. By Application
- 9.2.4. By End User
- 9.2.5. By Country
- 9.3. Asia-Pacific: Country Analysis
- 9.3.1. China Cancer Microbiome Sequencing Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.1.1. By Value
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Component
- 9.3.1.2.2. By Technology
- 9.3.1.2.3. By Application
- 9.3.1.2.4. By End User
- 9.3.2. India Cancer Microbiome Sequencing Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.1.1. By Value
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Component
- 9.3.2.2.2. By Technology
- 9.3.2.2.3. By Application
- 9.3.2.2.4. By End User
- 9.3.3. Japan Cancer Microbiome Sequencing Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Component
- 9.3.3.2.2. By Technology
- 9.3.3.2.3. By Application
- 9.3.3.2.4. By End User
- 9.3.4. South Korea Cancer Microbiome Sequencing Market Outlook
- 9.3.4.1. Market Size & Forecast
- 9.3.4.1.1. By Value
- 9.3.4.2. Market Share & Forecast
- 9.3.4.2.1. By Component
- 9.3.4.2.2. By Technology
- 9.3.4.2.3. By Application
- 9.3.4.2.4. By End User
- 9.3.5. Australia Cancer Microbiome Sequencing Market Outlook
- 9.3.5.1. Market Size & Forecast
- 9.3.5.1.1. By Value
- 9.3.5.2. Market Share & Forecast
- 9.3.5.2.1. By Component
- 9.3.5.2.2. By Technology
- 9.3.5.2.3. By Application
- 9.3.5.2.4. By End User
- 10. South America Cancer Microbiome Sequencing Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Component
- 10.2.2. By Technology
- 10.2.3. By Application
- 10.2.4. By End User
- 10.2.5. By Country
- 10.3. South America: Country Analysis
- 10.3.1. Brazil Cancer Microbiome Sequencing Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Component
- 10.3.1.2.2. By Technology
- 10.3.1.2.3. By Application
- 10.3.1.2.4. By End User
- 10.3.2. Argentina Cancer Microbiome Sequencing Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Component
- 10.3.2.2.2. By Technology
- 10.3.2.2.3. By Application
- 10.3.2.2.4. By End User
- 10.3.3. Colombia Cancer Microbiome Sequencing Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Component
- 10.3.3.2.2. By Technology
- 10.3.3.2.3. By Application
- 10.3.3.2.4. By End User
- 11. Middle East and Africa Cancer Microbiome Sequencing Market Outlook
- 11.1. Market Size & Forecast
- 11.1.1. By Value
- 11.2. Market Share & Forecast
- 11.2.1. By Component
- 11.2.2. By Technology
- 11.2.3. By Application
- 11.2.4. By End User
- 11.2.5. By Country
- 11.3. MEA: Country Analysis
- 11.3.1. South Africa Cancer Microbiome Sequencing Market Outlook
- 11.3.1.1. Market Size & Forecast
- 11.3.1.1.1. By Value
- 11.3.1.2. Market Share & Forecast
- 11.3.1.2.1. By Component
- 11.3.1.2.2. By Technology
- 11.3.1.2.3. By Application
- 11.3.1.2.4. By End User
- 11.3.2. Saudi Arabia Cancer Microbiome Sequencing Market Outlook
- 11.3.2.1. Market Size & Forecast
- 11.3.2.1.1. By Value
- 11.3.2.2. Market Share & Forecast
- 11.3.2.2.1. By Component
- 11.3.2.2.2. By Technology
- 11.3.2.2.3. By Application
- 11.3.2.2.4. By End User
- 11.3.3. UAE Cancer Microbiome Sequencing Market Outlook
- 11.3.3.1. Market Size & Forecast
- 11.3.3.1.1. By Value
- 11.3.3.2. Market Share & Forecast
- 11.3.3.2.1. By Component
- 11.3.3.2.2. By Technology
- 11.3.3.2.3. By Application
- 11.3.3.2.4. By End User
- 11.3.4. Turkey Cancer Microbiome Sequencing Market Outlook
- 11.3.4.1. Market Size & Forecast
- 11.3.4.1.1. By Value
- 11.3.4.2. Market Share & Forecast
- 11.3.4.2.1. By Component
- 11.3.4.2.2. By Technology
- 11.3.4.2.3. By Application
- 11.3.4.2.4. By End User
- 11.3.5. Egypt Cancer Microbiome Sequencing Market Outlook
- 11.3.5.1. Market Size & Forecast
- 11.3.5.1.1. By Value
- 11.3.5.2. Market Share & Forecast
- 11.3.5.2.1. By Component
- 11.3.5.2.2. By Technology
- 11.3.5.2.3. By Application
- 11.3.5.2.4. By End User
- 12. Market Dynamics
- 12.1. Drivers
- 12.2. Challenges
- 13. Market Trends & Developments
- 14. Competitive Landscape
- 14.1. Illumina, Inc.
- 14.2. Eurofins Scientific SE
- 14.3. QIAGEN NV
- 14.4. Thermo Fischer Scientific, Inc.
- 14.5. Oxford Nanopore Technologies plc.
- 14.6. OraSure Technologies, Inc.
- 14.7. Pacific Biosciences of California, Inc.
- 14.8. Psomagen, Inc
- 14.9. Prescient Medicine Holdings, Inc.
- 14.10. Micronoma Inc.
- 15. Strategic Recommendations
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook